Vista Pharmaceuticals Ltd, established in **1992**, is an Indian pharmaceutical entity specializing in the formulation, registration, and international distribution of generic drug products. The company holds a historic position as a pioneer in Indian pharmaceutical exports to regulated markets and currently operates a state-of-the-art manufacturing ecosystem in **Telangana, India**. --- ### Historical Milestones and Regulatory Leadership Vista Pharmaceuticals distinguishes itself through early entry into the highly regulated **United States** market. It was the first Indian company to secure **US-FDA** approvals for both **Over-the-Counter (OTC)** and **Prescription (Rx)** drugs. | Milestone / Product | Detail | Year | | :--- | :--- | :--- | | **US-FDA Approval** | First Indian company approved for OTC and Prescription drugs | **1994** | | **First Export** | First Indian company to export OTC/Rx drugs to the US | **1996** | | **Generic Bactrim** | US-FDA approval for **Sulfamethoxazole + Trimethoprim (SMZ)** | **Oct 2005** | | **US Launch** | Initial launch of **SMZ** product manufactured in the US | **May 2006** | | **Site Transfer** | US-FDA approval to transfer **SMZ** manufacturing to **India** | **June 2010** | | **India Export** | Launch of India-manufactured **SMZ** product into the US market | **Nov 2010** | | **WHO Certification** | Awarded **WHO Certificate** (Effective through **May 2025**) | **2023** | --- ### Manufacturing Infrastructure and Product Portfolio The company operates a single business segment focused on pharmaceutical, medical, and veterinary preparations. Its primary facility in **Nalgonda, Telangana**, is built to **cGMP** and **US-FDA** standards, integrating **R&D**, **Quality Assurance (QA/QC)**, and production. * **Dosage Forms:** Specialized production lines for **Tablets, Capsules, and Liquids**. * **Therapeutic Focus:** Historically strong in **Anti-infectives** (e.g., Sulfamethoxazole + Trimethoprim); currently pivoting toward chronic therapies including **Cardiovascular, Anti-diabetic, Anti-depressants, and Anti-cancer** treatments. * **Business Model Pillars:** * **ANDA Development:** Creating Abbreviated New Drug Applications for off-patented branded drugs. * **Contract Manufacturing:** Providing manufacturing services for third-party pharmaceutical firms. * **Related Party Synergy:** Supplying formulations to related companies under common directorship to optimize capacity. --- ### Strategic Growth Initiatives and Joint Ventures Vista is pursuing a transition from a pure-play generic manufacturer to a specialty pharmaceutical provider through high-margin therapeutic categories. * **Pleiades Therapeutics Partnership:** In **February 2026**, Vista entered a **Joint Venture** with **Pleiades Therapeutics**. This collaboration merges Pleiades' **R&D expertise** with Vista’s manufacturing and marketing infrastructure to develop **Specialty Pharmaceutical Products** for the **US** and **Rest-of-the-World (ROW)** markets, specifically targeting **Cardiac, Respiratory, and CNS** drugs. * **Market Expansion:** Leveraging the fact that generics constitute **85%** of US prescriptions, the company is expanding its pipeline of off-patented versions of branded drugs. * **Backward Integration:** The company is exploring strategic investments in **Bulk Drugs (APIs)** to secure its supply chain and improve margins. --- ### Capital Structure and Financial Trajectory The company has been active in the capital markets to fund working capital and expansion, despite facing recent profitability headwinds. **Comparative Financial Performance:** | Metric (INR Crore) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **10.07** | **10.29** | **1.00** | | **Total Expenditure** | **15.81** | **15.80** | **7.28** | | **Loss Before Tax** | **(5.29)** | **(5.18)** | **(5.88)** | | **Profit/(Loss) After Tax** | **(4.65)** | **(4.51)** | **5.66** | | **Earnings Per Share (Rs.)** | **(0.79)** | **(1.03)** | **(1.54)** | **Recent Capital Raising Activities:** * **November 2025:** Issued **10,249,998 Convertible Share Warrants**, receiving an upfront subscription of **₹3.08 crore** (**25%** of total). * **March 2025:** Proposed issuance of **4,88,71,494 Convertible Warrants** at **₹12** each, totaling **₹58.65 Crore**. * **September 2023:** Preferential allotment of **1,73,54,676 Equity Shares** at **₹12.96**, raising **₹22.49 Crore**. * **Authorized Capital Growth:** Increased from **₹15 Crore** in 2023 to **₹23 Crore** (divided into **11.50 Crore** equity shares of **₹2** each) by 2025. --- ### Asset Management and Debt Profile Vista’s operational assets are managed under specific depreciation schedules, with factory land and buildings at **Gopalaipalli** serving as primary collateral for credit facilities. * **Banking Relations:** Primary credit facilities are held with **Bank of Baroda** at a floating interest rate of **15.50%**. * **Debt Instruments:** Includes a **Mortgage Loan (₹3.8 crore)**, **Working Capital Term Loan (₹4 crore)**, and a **Term Loan (₹63.50 lakh)**. * **Asset Useful Life:** Factory Buildings (**30-60 years**), Plant and Equipment (**15-25 years**), and Vehicles (**8-10 years**). * **Gearing Ratio:** Total debt stood at **₹7.96 crore** as of March 31, 2024, representing a gearing ratio of **0.16**. --- ### Corporate Governance and Shareholding The company is led by a board of **14 members**, maintaining a **50% Independent Director** ratio to comply with **SEBI (LODR)** regulations. * **Key Leadership:** * **Dr. Dhananjaya Alli**: Chairman & Whole Time Director. * **Mr. Murali Meraga**: Managing Director (Re-appointed in **Sept 2025** for 3 years; notably serving **without remuneration**). * **Mr. Suneel Pachipala**: Chief Financial Officer. * **Shareholding Pattern (March 31, 2025):** * **CDSL**: **54.9%** * **NSDL**: **37.94%** * **Physical Form**: **7.16%** * **Total Dematerialized**: **92.83%** --- ### Risk Factors and Mitigation Framework Vista operates in a high-risk environment characterized by stringent regulatory oversight and financial volatility. **1. Regulatory and Compliance Challenges:** * **BSE Penalties:** Faced a penalty of **₹2,98,40,000 plus 18% GST** for delays in listing applications. * **Statutory Dues:** Auditors noted "serious delays" in depositing **Provident Fund, ESI, Income Tax, and GST**. As of late 2025, outstanding dues included **TDS (₹16.87 lakh)** and **Income Tax (₹2.46 crore)**. * **Governance Gaps:** Historical non-compliance regarding the appointment of a **woman director** and delays in filling **Company Secretary** vacancies. **2. Operational and Financial Risks:** * **Credit Loss:** Recognized a provision for **Expected Credit Loss (ECL)** of **₹20.54 crore** in **Q2 2025** against long-pending trade receivables. * **Internal Controls:** Lack of external **balance confirmations** for receivables/payables; reliance on internal book balances. * **Commodity Volatility:** High exposure to **API price fluctuations** with no material derivative contracts currently in place to hedge these costs. **3. Risk Management Strategy:** | Risk Category | Management Strategy | | :--- | :--- | | **Market Risk** | Uses **forward covers** for net foreign exposure (primarily **USD**). | | **Interest Rate Risk** | Limited exposure due to a preference for **fixed interest rate** instruments. | | **Liquidity Risk** | Managed by maintaining sufficient funds for operational requirements; currently characterized as **minimal**. | | **Credit Risk** | Employs an **ECL model** and limits investments to high-rated liquid securities. |